- Home
- IMNN vs BCDA Comparison
IMNN vs BCDA Comparison
Compare IMNN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- BCDA
- Stock Information
- Founded
- IMNN 1982
- BCDA N/A
- Country
- IMNN United States
- BCDA United States
- Employees
- IMNN N/A
- BCDA N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- BCDA Health Care
- Exchange
- IMNN Nasdaq
- BCDA Nasdaq
- Market Cap
- IMNN 12.1M
- BCDA 11.0M
- IPO Year
- IMNN 1985
- BCDA N/A
- Fundamental
- Price
- IMNN $0.77
- BCDA $2.15
- Analyst Decision
- IMNN Buy
- BCDA Strong Buy
- Analyst Count
- IMNN 2
- BCDA 1
- Target Price
- IMNN $14.00
- BCDA $25.00
- AVG Volume (30 Days)
- IMNN 5.4M
- BCDA 52.3K
- Earning Date
- IMNN 08-13-2025
- BCDA 08-12-2025
- Dividend Yield
- IMNN N/A
- BCDA N/A
- EPS Growth
- IMNN N/A
- BCDA N/A
- EPS
- IMNN N/A
- BCDA N/A
- Revenue
- IMNN N/A
- BCDA $3,000.00
- Revenue This Year
- IMNN N/A
- BCDA N/A
- Revenue Next Year
- IMNN N/A
- BCDA N/A
- P/E Ratio
- IMNN N/A
- BCDA N/A
- Revenue Growth
- IMNN N/A
- BCDA N/A
- 52 Week Low
- IMNN $0.37
- BCDA $1.63
- 52 Week High
- IMNN $3.65
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- IMNN 40.14
- BCDA 51.13
- Support Level
- IMNN $0.93
- BCDA $1.98
- Resistance Level
- IMNN $1.03
- BCDA $2.45
- Average True Range (ATR)
- IMNN 0.18
- BCDA 0.17
- MACD
- IMNN -0.10
- BCDA 0.01
- Stochastic Oscillator
- IMNN 1.39
- BCDA 53.19
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).